Out of the STAT3 inhibitors, silibinin has been shown to have specific anti-inflammatory, antioxidant, antiproliferative, antimetastatic and anti-angiogenic action, and thus, it could have interesting antitumor activity against several types of cancers. The gene discussed is STAT3; the disease is cancer.